Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon
Q’Apel Medical 072 Aspiration System

Aspiration system for stroke thrombectomy recalled, discontinued after FDA raises concerns

The devices are being recalled and discontinued after the FDA shared a series of concerns. This is a Class I recall, meaning using this system could result in serious injuries or death.

Perfuze Millipede 088 catheter

Perfuze celebrates a ‘major milestone’ for new-look stroke catheter

The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels. 

Conavi Medical’s Novasight Hybrid System catheter

FDA warns that certain coronary imaging catheters are being removed from market over safety concerns

A catheter sheath detached during use and was left in the patient’s body. It was successfully removed, but the FDA said it is now evaluating the potential risk to others going forward. There is no official recall at this time.

meat diet grocery store deli

Mediterranean diets that include some lean red meat can still boost cardiovascular health

The study's authors focused on blood pressure reductions and arterial stiffness, sharing their findings in Current Developments in Nutrition.

Richard Kovacs, MD, MACC, chief medical officer, American College of Cardiology (ACC), former ACC president, and professor of clinical medicine, Indiana University School of Medicine, explains the most important late-breaking cardiology pharmacology trials at the ACC 2025 meeting. #ACC25 #ACC2025

Late-breaking cardiovascular drug trials took center stage at ACC.25

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

Semaglutide, the GLP-1 receptor agonist sold by Novo Nordisk under the brand names Wegovy and Ozempic, is associated with significant health benefits for patients with type 2 diabetes and peripheral artery disease (PAD), according to a late-breaking clinical trial presented at ACC.25, the annual meeting of the American College of Cardiology (ACC).

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Heart cardiologists doctors surgery

Strokes more likely for U.S. heart transplant recipients following policy change

A nationwide policy shift implemented in 2018 was designed to, among other things, improve the waiting list mortality rate. One unintended consequence, however, is that patients are now more likely to experience a stroke after receiving a new heart.

Eric Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, director of vascular intervention, Beth Israel Deaconess, section head, interventional cardiology and vascular research, Susan F. Smith Center for Outcomes Research, and associate professor of medicine, Harvard Medical School, explained some of the new bioresorbable stent scaffold technology that is being developed for use in PAD below the knee at CRT 2025.

Advances in bioresorbable stents show promise for treating PAD

Bioresorbable stents are back in the spotlight thanks to some significant progress from multiple medtech companies. Eric Secemsky, MD, discussed some of the biggest breakthroughs in this space at CRT 2025.

Displaying 17 - 24 of 836
Design by Adaptive Theme